CSIMarket
 
Acasti Pharma Inc   (ACST)
Other Ticker:  
 
 
Price: $3.4000 $0.00 0.000%
Day's High: $3.4 Week Perf: 0.00
Day's Low: $ 3.30 30 Day Perf: 0.00
Volume (M): 27 52 Wk High: $ 3.76
Volume (M$): $ 91 52 Wk Avg: $2.09
Open: $3.38 52 Wk Low: $0.43



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Acasti Pharma Inc
Acasti Pharma Inc is a pharmaceutical company that specializes in the research and development of prescription drugs for various medical conditions. The company is known for its focus on developing innovative treatments for cardiovascular diseases, including a particular emphasis on the use of omega-3 fatty acids. Acasti Pharma aims to provide safe and effective pharmaceutical solutions to improve the quality of life for patients suffering from these conditions. The company is based in Canada and operates with a vision to become a global leader in cardiovascular drug development.


   Company Address: 2572 boul. Daniel-Johnson, 2nd Floor Laval 0 QC
   Company Phone Number: 686-4555   Stock Exchange / Ticker: NASDAQ ACST
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Acasti Pharma Inc

Acasti Pharma Inc Reveals Operating Loss of $2.092 Million in Sep 30 2023 Report

Acasti Pharma Inc Shows Promising Signs of Recovery with Improved Financials
The Major Pharmaceutical Preparations sector has been closely watched by investors and market analysts for its potential to yield significant returns. Among the key players in this sector, Acasti Pharma Inc (ACST) stands out as a rising star, as indicated by its recent financial reports.
In the second quarter of 2024, Acasti Pharma Inc reported an operating loss of $-2.092 million, a significant improvement from the operating loss of $-5.108 million in the same period of 2022. This positive development signals a step in the right direction for the company.

Acasti Pharma Inc

Acasti Pharma Inc Reports Significant Improvement in Operating Loss, Reflecting a -$4.73 Million Improvement in the Most Recent Fiscal Period



As the earnings season for the April to June 2023 period progresses, various companies have disclosed their earnings, with entities in the Major Pharmaceutical Preparations industry catching the attention of investors. Acasti Pharma Inc (ACST) is one such company that recently announced its financial results, reporting an operating loss of $-4.454 million for the fiscal span closing on June 30, 2023.
This news has been welcomed by investors, seeing it as a positive development for ACST, particularly when compared to the operating loss of $-4.73 million in the first quarter of 2022. The management's efforts to make the company more cost-effective have shown results, as they have successfully reduced diminishing returns to $-4.023 million during the April to June 30, 2023 financial interval.
While the value of accounts receivable remains below the previous year level, there has been sequential improvement, indicating progress in the company's operations. This data provides investors with further affirmation in ACST's prospects.

Acasti Pharma Inc

Acasti Pharma Inc Reports Operating Shortfall of $38.072 million in Q4 2023 Amidst Evolving Pharmaceutical Preparations Market

The Major Pharmaceutical Preparations industry advisors are currently analyzing the financial performance of Acasti Pharma Inc for the fourth quarter of 2023. The company has reported an operating shortfall of $-38.072 million for the period from January to March 31, 2023. It is important to note that Acasti Pharma Inc has not reported any revenue yet for this quarter.
To understand the significance of the financial data for the fourth quarter of 2023, it is useful to compare it with the figures from the previous year. In the fourth quarter of 2022, the operating shortfall was $-4.403 million. It is not surprising that the evolving business has recorded a larger shortfall of $-29.087 million in the corresponding time frame of the previous year, compared to $-3.904 million.
In the financial year 2023, the Major Pharmaceutical Preparations company has announced a shortfall of $-42.43 million and zero revenue. This data is concerning and indicates a financial struggle for the company in the given period. Moreover, the net shortfall per share has increased from $-0.27 in the prior financial year to $-0.95 in the current year. It is important to note that there has been no significant change in revenue from $0.00 million a year before.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com